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Simplified antibiotic regimens for treating young infants in the 
Democratic Republic of Congo with possible severe infection: a 
comparative effectiveness trial 
 
ABSTRACT 
One-quarter of neonatal and infant deaths are due to infection, and the 
majority of these deaths occur in developing countries. A significant reduction 
in infant mortality in these countries will not occur without a reduction in 
deaths due to infection. We participated in a multi-national study that 
demonstrated the effectiveness of three simplified antibiotic regimens compared 
to standard treatment. For this report, we examined the site-specific data for 
the Democratic Republic Congo (DRC), the most impoverished of the countries 
that participated in the study, to determine if outcomes in the DRC were 
similar to outcomes across all sites. This randomized controlled trial enrolled 
1,842 infants, of whom 1805 met the per-protocol criteria for study analysis. 
The main outcome was treatment failure within the first week of enrollment. 
Treatment failure occurred in 123 (6.7%) infants: 30 (6.6%) in Arm A, 36 (8.2%) 
in Arm B (risk difference 1.6%; 95% CI -1.8% to 5%), 29 (6.3%) in C (-0.3%, -
3.4% to 3%), and 28 (6.1%) in C (-0.5%, -3.6% to -2.7%). The risk difference 
between each of the experimental treatments and the reference treatment 
suggests equivalence. These findings suggest that a simplified antibiotic 
regimen can be used for the community-based management of possible severe 
infection in young infants where referral to a hospital for standard care is often 
not possible. We speculate that the widespread use of a simplified, community-
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based treatment could result in increased coverage with treatment and 
improved survival in poor areas. 
INTRODUCTION 
Among the Millennium Development Goals (MDGs), those that target 
significant reductions in maternal and child mortality have proven the most 
difficult to achieve. There has been only limited progress towards these goals in 
many parts of the world. An estimated 3.1 million neonatal deaths occurred in 
2010.  These accounted for 40% of deaths in children. The persistent high 
neonatal mortality rate in many countries is a major obstacle to the 
achievement of MDG4, reduction in child mortality.1  
Although neonatal mortality has declined in high-income countries over the 
past several decades, it is still one of the main public health problems in 
developing countries. Neonatal mortality fell from 33 deaths per 1,000 live 
births in 1990 to 21 deaths per 1,000 births in 2012, but the magnitude of 
reductions in South Asia and sub-Saharan Africa (39% and 28%, respectively) 
was lower than in other regions.2 In 2009 more than 50 percent of all neonatal 
deaths occurred in five countries: India 27.8%, Nigeria 7.2%, Pakistan 6.9%, 
China 6.4%, and the Democratic Republic of the Congo 4.6%.3 Achieving 
MDG4 will require effective interventions to reduce neonatal mortality in these 
countries.  
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Infection is one of the leading causes of neonatal mortality, accounting for 
about 25 percent of neonatal deaths.4 Early-onset neonatal sepsis, defined as 
occurring within the first 72 hours after birth, is associated with vertical 
transmission of microorganisms present in the mother’s genitourinary tract.5 
Group B Streptococcus (GBS), Escherichia coli, Haemophilus influenza, and 
Listeria monocytogenes are among the microorganisms commonly identified in 
early-onset neonatal sepsis.4 Late-onset sepsis is more likely to result from an 
unhygienic environment and is commonly due to Coagulase-negative 
Staphylococcus, Staphylococcus aureus, Escherichia coli, Klebsiella, 
Pseudomonas, and Enterobacter. 
A number of preventive strategies appear to reduce the likelihood of infection. 
These include clean delivery practices, prompt treatment of chorioamnionitis, 
early and exclusive breastfeeding, eye prophylaxis, and hygienic skin and 
umbilical cord care.6-8 A set of simple, preventive interventions reduced the 
incidence of sepsis by 30 percent in a remote district of India.9 Umbilical cord 
cleansing with chlorhexidine and emollient therapy for preterm babies are 
promising interventions.10-12  
When prevention of infection fails, neonatal sepsis often results in death. Case 
fatality can be as high as 22 percent without effective therapy.13 It is estimated 
that appropriate treatment could reduce infection-specific mortality by 30-70 
percent, making it an important intervention for improving child survival and 
meeting the MDG4 targets.14 
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In the U.S., infants with suspected infections are generally treated with 
intravenous antibiotics for at least10 days in an inpatient setting.15 Ampicillin 
along with an aminoglycoside is generally used as initial therapy, because 
these antibiotics are appropriate for the common pathogens, i.e., GBS, Listeria 
monocytogenes, and E. coli.16, 17 According to the World Health Organization 
(WHO), infants with possible serious bacterial infections should be referred to a 
hospital and treated with a combination of injectable gentamicin and 
penicillin/ampicillin for at least 7-10 days.18 
While there is little doubt about the efficacy of the recommended treatment in 
reducing the risk of death of young infants with possible serious bacterial 
infection, most of these infants do not currently receive inpatient care in most 
developing countries, including the Democratic Republic of Congo (DRC).  
There are several reasons for the lack of compliance in the DRC with this WHO 
recommendation. First, nearly all health care in rural areas is provided through 
health centers, and these centers do not typically provide inpatient care.  
Health centers refer some patients to their area hospital if inpatient care is 
advisable and feasible.  However, distances from health centers to hospitals 
vary widely, ranging from less than 1 mile to 60 miles, and transportation is 
challenging. In addition, inpatient care is often not available because of 
inadequate and poorly equipped hospitals.19 
From 2010 to 2013, a rural area of the DRC participated in a multi-national 
study that examined the effectiveness of four simplified regimens of antibiotic 
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therapy for the treatment of serious bacterial infection in neonates and young 
infants. The results of that study suggest that these infections could be treated 
effectively in health centers or homes. However, each of the five sites in three 
countries had unique demography, geography and healthcare infrastructure 
that might predict variation in effectiveness among sites. The objective of this 
report was to examine the comparative effectiveness of these treatment 
regimens in the cohort enrolled in the DRC, the most rural and impoverished 
environment among the study sites, by examining the DRC site-specific data 
from the multi-national study. 
METHODS 
Study design 
The multi-national study was an individually randomized, open-label, 
equivalence trial.20 The data reported here are from the DRC site only. The 
study randomized young infants with signs of serious bacterial infection to one 
of four community-based antibiotic treatment regimens. 
 Description of the study site 
The study was conducted in the province of Equateur which is in the north-
west part of the country. Infants resided in the North and South Ubangi health 
districts. In these districts, we selected the following health zones: Karawa, 
Bominenge, Bogose-Nubea, and Budjala. We enrolled infants in the following 
communities (clusters): Karawa, Gbosasa, Bodadi, Bominenge, Takaya, Bongo, 
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and Budjala. The target population in those clusters was 322,746 inhabitants, 
averaging approximately 16,000 births per year over the past decade. 
Study participants 
Young infants, 0 to 59 days of age, with possible serious bacterial infection and 
whose families did not accept or could not access inpatient hospital care were 
considered for participation in the study. 
Inclusion criteria:  
 any of the following: not feeding well, movement only when stimulated, 
severe chest indrawing and axillary temperature >38.0°C or <35.5°C 
 parents not accepting hospital referral 
 parents giving consent to participate in the study 
Exclusion criteria:  
 having very low weight (<1500g at the time of presentation) 
 being hospitalized for illness in the previous two weeks or prior inclusion 
in the study 
 exhibiting any sign of critical illness: unconscious, convulsions, unable 
to feed at all, apnea, unable to cry, cyanosis, dehydration, bulging 
fontanel 
 having any of the following conditions: major congenital malformations 
inhibiting oral antibiotic intake, active bleeding requiring transfusion, 
surgical conditions needing hospital referral, persistent vomiting defined 
8 | P a g e  
 
as vomiting following three attempts to feed the baby within one-half 
hour 
Active surveillance 
A system of active surveillance for the identification of pregnancies, births, and 
sick infants was established in all study communities. Before the beginning of 
the trial, community health workers (CHWs) conducted a household census in 
order to identify all births and pregnant women. Household censuses were 
repeated every three to four months. Other methods were also used to discover 
pregnancies and births: self-reporting to a CHW, identification at antenatal 
clinics in the community health facilities, and information from traditional 
birth attendants (TBAs) or other key informants. CHWs visited the homes of 
newborns on days 1, 3, 7, 14, 21, 28, 35, 42, 49 and 60 after birth. During 
these home visits, the CHWs provided standardized advice regarding newborn 
care, as described in the WHO/UNICEF Joint Statement on home-based care of 
newborns, 21 including: early and exclusive breastfeeding, maintenance of body 
temperature using skin-to-skin contact, hand-washing prior to handling infant, 
hygienic umbilical cord care, and recommendations regarding adherence to a 
vaccination schedule. At each home visit, CHWs assessed the newborn for 
signs of illness and counseled the families on recognition of danger signs (stops 
feeding well, convulsions, fast breathing, severe chest in-drawing, temperature 
> 37.5°C or < 35.5°C, movements only on stimulation, yellow soles, or pus from 
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umbilicus, eye or skin). Young infants who exhibited any of these signs were 
advised to go to a health center. 
Informed consent procedure, screening and enrollment 
Infants referred to health centers by CHWs, as well as those who were self-
referred by their parents or guardians, were seen by a study nurse. If the study 
nurse confirmed the danger sign, the infant was referred to facility local 
hospital, as recommended in the WHO Integrated Management of Children 
Illness (IMCI) guidelines.22   
If the family refused to accept hospital referral despite the best efforts of the 
study nurse, they were considered for enrollment in the study if all other 
inclusion criteria were met, and none of the exclusion criteria were present. 
Consent for study participation was obtained by the study nurse at the health 
facility or at home in the presence of a witness. Consent included detailed oral 
communication in the study participant’s native language to ensure 
comprehension of the trial and study procedures. Illiterate parents were asked 
to provide a thumbprint on the consent form; literate parents were requested to 
sign the consent form. 
Randomization and allocation concealment 
Prior to randomization, infants were categorized by type of presentation as 
having either severe infection or fast breathing only. Severe infection included 
all presenting signs and symptoms except fast breathing only. Infants were 
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stratified on type of presentation and age at presentation (< 7 days old and 7 to 
59 days old). Four block-randomization schemes in block sizes of 8 were 
computer-generated off-site using STATA version 10.0 by a person not involved 
with the study. For allocation concealment, the treatment code for each study 
infant was sealed in an envelope; one color for each age stratum. Two color-
coded envelopes for within age stratum were used to randomize infants within 
each stratum of presentation (severe infection and fast breathing only). Each 
cluster was given envelopes for a set of blocks, and used blocks were regularly 
replaced so that a constant number of envelopes were always available in the 
community. When the first infant was enrolled in a community in a stratum, 
the first envelope of the first block for that presentation and age stratum and 
age category at the health center was opened and the infant was treated 
according to the treatment code inside. When the next infant was enrolled, the 
next envelope of the block was opened.   
Treatment Regimens 
Treatment Regimen A (reference treatment): injection of gentamicin once daily 
and injection of procaine penicillin once daily for 7 days (14 injections in total). 
Treatment Regimen B:  injection of gentamicin once daily and oral amoxicillin 
twice daily for 7 days (7 injections in total). 
Treatment Regimen C: injection of gentamicin once daily and injection of 
procaine penicillin once daily for 2 days; thereafter oral amoxicillin for 5 days 
(4 injections in total). 
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Treatment Regimen D: injection of gentamicin once daily and oral amoxicillin 
twice daily for 2 days; thereafter oral amoxicillin twice daily for 5 days (2 
injections in total).  
Treatment  
This was an open (un-blinded) study because a multiple injection regimen was 
compared to single injection-oral regimen combinations; blinding participants 
and investigators by using placebo injections would thus not be justifiable 
(Figure 1). 
All treatments were given at a health center or at home. The injections were 
given once daily by the study nurse at a health center or at home, while oral 
medicines were given under supervision of CHWs at home. Mothers observed 
the first dose being given, then were instructed to provide the second daily dose 
of oral amoxicillin at home in the same manner. Daily assessment by the study 
nurse was conducted to identify worsening of any critical signs.  Home visits to 
assess the outcome of the treatment were conducted by an independent 
outcome assessment nurse at day 4, 8, 11 and15 to detect any treatment 
failure. 
Study outcomes 
Treatment failure within day 1-8 following enrollment was the primary outcome 
and was defined as any one of the following:  
 Death 
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 Clinical deterioration (hospitalization, emergence of any sign of critical 
illness, a new sign of severe infection, or re-emergence of a sign of severe 
infection on day 4 after it had initially disappeared) 
 No improvement in clinical condition by day 4 (if single sign of severe 
infection at enrollment, persistence of the sign, and if multiple signs at 
enrollment, persistence of >1 sign) 
 Not cured by day 8 (persistence of any sign of severe infection on day 8 of 
enrollment) 
 Development of a serious adverse effect to the study antibiotics 
 Withdrawal of informed consent, any time between days 1-8 
Data collection 
Standard case report forms were used to collect data. Data were double-
entered into a SQL database. A clean copy of the database was sent monthly to 
the central data coordination center at the London School of Hygiene and 
Tropical Medicine (LSHTM) for quality checks. 
Sample size and analysis plan 
For the DRC site, a sample size of approximately 450 per group ensures 86% 
statistical power to demonstrate equivalence between treatments based on the 
95% confidence interval for the risk difference of treatment failure. 
The analysis was conducted using STATA version 13.0. The primary analysis 
was per-protocol, which is considered a more conservative analysis than 
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intention to treat (ITT) analysis for equivalence studies. The primary outcome 
was treatment failure. The difference in the risk of treatment failure between 
the reference arm (Regimen A) and all other treatment arms together with a 
95% confidence interval was calculated. Secondary analyses were performed to 
investigate adverse events including death and other serious outcomes. 
RESULTS 
From April 2011 to May 2013, we enrolled 1842 infants. Among these, 779 
(42.3%) were enrolled in their first week of life. The randomization process 
allocated 464 infants to Arm A, 447 infants to Arm B, 465 infants to Arm C, 
and 466 infants to Arm D. 
Table 1 lists the baseline characteristics of study infants. All of these were 
similar among the four treatment regimens.  With regard to the place of birth, 
421 (22.8%) infants were born at home and 1213 (65.8%) infants were born at 
health centers. The mean weight-for-age z score study infants was below zero, 
the mean of the reference population used by WHO (Figure 2). About 21% were 
stunted (weight-for-age Z score <-2). The mean age of mothers was 25, and 339 
(18.4%) mothers were less than 20 years old. Approximately one-third of 
mothers (33.6%) had more than 4 living children, and 96% of mothers attended 
at least one antenatal clinic visit. The majority of mothers (52.3%) had no 
formal education, and 46.8% had less than 12 years of education.  
14 | P a g e  
 
The signs commonly present at enrollment were fever (32.9%) and fast 
breathing (32.7%) (Figure 3); 314 (17.0%) infants were enrolled with two or 
more signs. 
We excluded 37 infants from our analysis of treatment effect because they did 
not receive all treatment doses and adequate follow-up as required by the study 
protocol. Infants whose parents declined treatment at some point (n=12) but 
who had adequate assessment and follow up were categorized as treatment 
failures. Most of these infants were in Arm (n=5). 
Among the 1805 infants who met the treatment and assessment criteria, 454 
(25.2%) were allocated to Arm A, 437 (24.2%) to Arm B, 457 (25.3%) to Arm C, 
and 457 (25.3%) to Arm D. Almost all infants (98%) received all treatment 
doses as per-protocol analysis, and 1804 (98%) infants received all independent 
outcome assessment visits (Table 2).  
Treatment failure occurred in 123 (6.7%) infants: 30 (6.6%) infants allocated to 
Arm A, 36 (8.2%) to Arm B (risk difference: 1.6%; 95% CI: -1.8%–5%), 29 (6.4%) 
to Arm C (-0.3%; -3.4%–3%), 28 (6.1%) to Arm D (-0.5%; -3.6%–2.7%) (Table 3). 
Among treatment failures, 32 infants died; 23 had the appearance or a sign of 
critical illness; 17 had a new sign of serious infection; 17 were hospitalized; 
and 35 had no improvement in clinical condition by day 4. The signs that 
either did not improve or were new and resulted in the classification of 
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treatment failure were fast breathing (31%) and chest indrawing (23%) (Figure 
4). Treatment failure occurred mostly on day 4 of enrollment (Figure 5). 
DISCUSSION 
A multi-national study investigated the safety and effectiveness of simplified 
regimens for the management of possible serious bacterial infection among 
infants in resource-poor community settings.  This study enrolled 3564 infants 
in five sites (Kenya, DRC, and Nigeria: Ibadan, Zaria, Ile-Ife). Four week-long 
treatment regimens were compared. The outcomes of infants treated with three 
regimens of antibiotics that included combinations of parenteral 
(intramuscular) and oral antibiotics were compared to outcomes in a reference 
group treated with daily doses of parental antibiotics, the standard care. 
Among the 3364 infants, treatment failure occurred in 229 (6.8%) infants, but 
the risk differences between the experiment treatment regimens and the 
reference treatment was not statistically different, falling within the pre-
specified +5% similarity margin. The conclusion from this study was that 
treatment with these regimens was equivalent to the standard care.  
These findings were similar to results from previous studies. Community-based 
interventions involving CHWs in the prevention and promotion of maternal and 
newborn health proved effective in rural Pakistan and in Gadchiroli, India.13, 23 
A field trial conducted in rural India decreased case fatality of neonatal sepsis 
from 16.6% to 2.8% after the intervention of CHWs, thus confirming the 
feasibility, the acceptability, and the relevance of home-based strategies for 
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newborn care, as well as the management of neonatal severe infection in poor 
settings.24, 25 A cluster-randomized trial demonstrated that pregnancy and 
postnatal surveillance visits by CHWs reduced neonatal mortality rate by 53% 
in Uttar Pradesh, India.26 All these studies were observational and not 
individually randomized. However, a randomized controlled study evaluating 
the effectiveness of three simplified, community-based antibiotic regimens 
demonstrated the superiority of the combination of procaine penicillin and 
gentamicin over oral antibiotics. 27 Interestingly, ceftriaxone proved less 
effective. Although this study suggests that oral antibiotics may not be as 
effective as parental antibiotics, and would contradict the findings of our multi-
national trial, the sample size was small, increasing the likelihood that results 
occurred by chance alone.  
The purpose of the study reported in this manuscript was to determine 
whether the results from the multi-national study could be reasonably 
extrapolated to the DRC. The DRC is a unique environment compared to the 
other sites in terms of several factors. First, mothers had less education 
compared to other sites. The majority of mothers (52.3%) had no formal 
education, whereas the mean for all sites was about 17%. This is consistent 
with the DHS 2007 which found 41% and 50.3% of illiterate women of 
reproductive age in the DRC and in the Equateur province, respectively.28 
Second, the socio-economic status is lower in the DRC. Despite the abundant 
natural resources of the country, the population of the DRC is among the 
poorest in the world.29, 30 According to the 2013 Human Development Report, 
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the DRC ranks last with a poverty ratio of about 80%.31 Third, the DRC has 
high fertility rates and bigger families. The total fertility rate in the DRC is 
6.3,28 which is the highest among all the study sites. 
As in the multi-national study, we examined the safety and efficacy of 
simplified antibiotic regimens compared with the reference treatment for the 
management of neonates and young infants with suspected severe bacterial 
infection. Our study found evidence for similarity between each of the 
experimental treatment regimens and the reference treatment. Treatment 
failure varied among groups from 6.1% to 8.2%. Treatment regimen D, which 
had only two injections of gentamicin, had the smallest proportion (6.1%) of 
treatment failure. The risk difference in treatment among the three simplified 
regiments and the reference treatment varied from -0.5% to 1.6%. Neither the 
rate of treatment failure nor the risk difference was statistically different among 
treatment groups. Among the danger signs for which infants were recruited, 
chest fast breathing (31%) and chest indrawing (23%) were the leading causes 
of treatment failure. Most treatment failures occurred on day 4, and the most 
common reason for treatment failure was the persistence of the danger signs 
on day 4. These findings are similar to those observed in the multi-national 
study. In view of these findings, it can reasonably be inferred that treatment 
regimens tested in the multi-national study would be equally effective in the 
DRC. 
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Strengths and limitations 
This is the first study in the DRC that compared treatment regimens for the 
management of neonatal severe bacterial infection. The study was conducted 
within the context of the existing health structure. Therefore, the study 
methodology could be used as a model for capacity-building of the existing 
health system, and we believe that this strategy of care could be scaled up 
without difficulty. The study was conducted in one of the poorest regions of the 
country. The confirmation of effectiveness in this area suggests that the 
effectiveness of these simplified treatments can be generalized to more affluent 
areas of the country. The protocol was highly supervised; eligibility was 
confirmed by specially trained study nurses and assessment visits were 
conducted by the most qualified nurses among them who were not part of the 
clinical care team. 
This study also had some limitations. Although we had sufficient statistical 
power to demonstrate equivalence between treatments, the multi-national 
study was not powered for site-specific outcomes. Therefore, the results should 
be interpreted with some caution. The low mortality rate among all treatment 
groups may reflect the intense surveillance of the population. This close 
surveillance may have resulted in earlier identification of high-risk infants and 
earlier referral for health care. Later identification might have occurred in the 
absence of the study resulting in more severe illness at the initiation of 
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antibiotic treatment.  This might result in less effectiveness of simplified 
treatment regimens and higher mortality. 
Implications of the results 
Community-based treatments are more practical because they do not require 
inpatient care that is not available to many children in rural areas of the DRC. 
The most simplified treatment regimen may be particularly useful because it is 
based primarily on oral treatment. We speculate that the widespread use of 
this strategy for treating neonates and young infants with serious bacterial 
infection would result in more infants treated more effectively. This, in turn, 
would reduce mortality among young infants. 
CONCLUSION 
Simplified antibiotic regimens for treating infants in rural DRC with possible 
severe bacterial infection appear to be acceptable, feasible, safe, and effective. 
Since the most simplified regimen using mainly oral antibiotic and only two 
injections proved as effective as the WHO-recommended treatment, scaling up 
this regimen will more likely result in more infants treated effectively and result 
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Table 1: Baseline characteristics of enrolled infants 
  Study interventions 
  Arm A (%) Arm B (%) Arm C (%) Arm D (%) 
Total enrolled 464 447 465 466 
Age (days) Mean (SD) 15.8 (15.5) 15.6 (15.3) 15.5 (16.1) 15.9 (15.8) 
 < 7 days 196 (42.2) 187 (41.8) 203 (43.6) 193 (41.4) 
 ≥ 7 days 268  (57.8) 260 (58.2) 262 (56.4) 273 (58.6) 
Sex Males 251 (54.1) 235 (52.6) 245 (52.7) 243 (52.1) 
 Females 213 (45.9) 212 (47.4) 220 (47.3) 223 (47.9) 
Weight for age    (Z 
score) 
Mean Z score 
(SD) 
-1.2 (1.2) -1.03 (1.2) -1.3 (1.3) -1.2 (1.2) 
 < -2z scores 94 (20.3) 81 (18.1) 110 (23.7) 105 (22.5) 
 >=-2z scores 370 (79.7) 366 (81.9) 355 (76.3) 361 (77.5) 
Respiratory rate  Mean (SD) 67.7 (18.3) 67.9 (19.3) 67.3 (19.3) 66.4 (18.2) 
 < 60 180 (38.8) 177 (39.6) 194 (41.7) 199 (42.7) 
 60-70 76 (16.4) 73 (16.3) 80 (17.2) 66 (14.2) 
 70-79 88 (19) 79 (17.7) 80 (17.2) 93 (20) 
 80-89 65 (14) 55 (12.3)  52 (11.2) 59 (12.7) 
 90-99 31 (6.7) 30 (6.7) 32 (6.9) 27 (5.8) 
 ≥ 100 24 (5.2) 33 (7.4) 27 (5.8) 22 (4.7) 
Temperature < 35.5 53 (11.4) 61 (13.6) 79 (17) 64 (13.7) 
 35.5–37.9 125 (26.9) 146 (32.7) 117 (25.2) 123 (26.4) 
 ≥38.0–38.9 260 (56) 217 (48.5) 245 (52.7) 248 (53.2) 
            ≥39.0 26 (5.6) 23 (5.1) 24 (5.2) 31 (6.7) 
Poor feeding  98 (13.6) 98 (21.9) 93 (20) 111 (23.8) 
Movement only on 
stimulation 
 19 (26.7) 17 (3.8) 12 (2.6) 16 (3.4) 
Severe chest 
indrawing 
 103 (60.1) 107 (23.9) 97 (20.9) 94 (20.2) 
Number of signs at 
enrollment 
1 381 (82.1) 375 (83.9) 391 (84.1) 381 (81.8) 
 2 72 (15.5) 66 (14.8) 62 (13.3) 74 (15.9) 
 3 11 (2.4) 5 (1.1) 8 (1.7) 10 (2.1) 
 4 0 (0) 1 (0.2) 4 (0.9) 1 (0.2) 
Maternal age (years) Mean (SD) 25.9 (6.6) 24.9 (6.5) 25.2 (6.3) 24.8 (5.9) 
 < 20 years 82 (17.7) 88 (19.7) 84 (18.1) 85 (18.2) 
 ≥ 20 years 310 (66.8) 284 (63.5) 320 (68.8) 308 (66.1) 
 Unknown 72 (15.5) 75 (16.8) 61 (13.1) 73 (15.7) 
Place of birth Home 94 (20.3) 104 (23.3) 106 (22.8) 117 (25.1) 
 Hospital 40 (8.6) 33 (7.4) 32 (6.9) 24 (5.2) 
 Health center 303 (65.3) 296 (66.2) 306 (65.8) 308 (66.1) 
 Other 26 (5.6) 14 (3.1) 21 (4.5) 17 (3.6) 
 Unknown 1 (0.2) 0 (0) 0 (0) 0 (0) 
 
Number of live births 1 110 (23.7) 118 (26.4) 114 (24.5) 114 (24.5) 
 2-3 178 (38.4) 187 (41.8) 198 (42.6) 200 (42.9) 
 ≥4 175 (37.7) 141 (31.5) 152 (32.7) 152 (32.6) 
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 Unknown 1 (0.2) 1 (0.2) 1 (0.2) 0 (0) 
At least one 
antenatal clinic 
attendance 
Yes 442 (95.3) 434 (97.1) 449 (96.6) 446 (95.7) 
 No 22 (4.7) 13 (2.9) 16 (3.4) 20 (4.3) 
Religion Christian 464 (100) 446 (99.8) 463 (99.6) 466 (100) 
 Muslim 0 (0) 0 (0) 1 (0.2) 0 (0) 
 Other 0 (0) 1 (0.2) 1 (0.2) 0 (0) 
Maternal education 
(in years) 
Mean (SD) 5.1 (2.7) 5 (2.5) 5.4 (2.4) 5.2 (2.3) 
 No formal school 
attendance 
243 (52.4) 241 (53.9) 238 (51.2) 242 (51.9) 
 < 12 years 213 (45.9) 201 (45) 224 (48.2) 221 (47.4) 
 ≥ 12 years 8 (1.7) 5 (1.1) 3 (0.6) 3 (0.6) 
 Unknown 1 (0.2) 0 (0) 0 (0) 0 (0) 
 
Cooking place Indoor with solid 
fuel 
262 (56.5) 243 (54.4) 256 (55.1) 266 (57.1) 
 Outdoor with 
solid fuel 
202 (43.5) 204 (45.6) 209 (44.9) 200 (42.9) 
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Table 2: Treatment adherence and follow up of enrolled infants 
 Treatment regimens 
 Arm A Arm B Arm C Arm D 
Number of enrolled infants 464 447 465 466 
Treatment adherence     
Received all treatment doses as per-
protocol 
452 (97.4) 441 (98.7) 455 (97.8) 457 (98.1) 
Did not receive all doses, but met per-
protocol analysis criteria 
3 (0.6) 2 (0.4) 2 (0.4) 0 (0) 
Did not meet per-protocol analysis criteria 
for treatment 
9 (1.9) 4 (0.9) 8 (1.7) 9 (1.9) 
Follow up by independent outcome assessor 
Received all independent outcome 
assessment visits 
452 (97.4) 434 (97.1) 462 (99.4) 456 (97.9) 
Did not receive all independent outcome 
assessment visits, but met per-protocol 
analysis criteria 
6 (1.3) 6 (1.3) 2 (0.4) 6 (1.3) 
Did not meet per-protocol analysis criteria 
for assessment 
6 (1.3) 7 (1.6) 1 (0.2) 4 (0.9) 
Included in per-protocol analysis (met 
both treatment and assessment criteria) 
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Table 3: Primary and secondary outcomes in enrolled infants–per-protocol analysis 
 Treatment regimens 
 Arm A Arm B Arm C Arm D 
Total enrolled 464 447 465 466 
Met per-protocol analysis criteria 454 (97.8) 437 (97.8) 457 (98.3) 457 (98.1) 
First week after enrollment  
Primary outcome: treatment 
failure by per-protocol analysis 
30 (6.6) 36 (8.2) 29 (6.3) 28 (6.1) 
      Risk difference 
(95% CI) 
- 1.6%         
 (-1.8%–5%) 
-0.3%                
 (-3.4%–3%) 
-0.5%          
 (-3.6%–2.7%) 
Reason for treatment failure     
      Death  3 (0.7) 11 (2.5) 12 (2.6) 6 (1.3) 
      Appearance of a sign of critical 
illness 
6 (1.3) 6 (1.4) 7 (1.5) 4 (0.9) 
      Appearance of a new sign of 
serious infection 
2 (0.4) 7 (1.6) 4 (0.9) 4 (0.9) 
      SAE other than death 0 (0) 0 (0) 0 (0) 1 (0.2) 
      Hospitalization 4 (0.9) 4 (0.9) 5 (1.1) 2 (0.4) 
      No improvement in clinical 
condition by day 4 
14 (3.1) 10 (2.3) 2 (0.4) 9 (2) 
      Reappearance of inclusion sign 
between days 5-8 
4 (0.9) 2 (0.5) 4 (0.9) 5 (1.1) 
      Presence of inclusion sign on 
day 8 
1 (0.2) 0 (0) 0 (0) 0 (0) 
Withdrawal from the study (per-
protocol withdrawal 
excluded) 
5 (1.1) 1 (0.2) 4 (0.9) 2 (0.4) 
      Risk difference - -40%         
 (-76%, -3.8%) 
0%                     
 (-46.4%, 46.4%) 
-27.7%        
 (-68.9%, 13.4%) 
Second week after enrollment     
Death 0 (0) 0 (0) 2 (0.4) 1 (0.2) 
SAE other than death 0 (0) 0 (0) 0 (0) 0 (0) 
First and second week after 
enrollment 
    
Death (% out of all enrolled) 4 (0.9) 11 (2.5) 14 (3) 7 (1.5) 
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Figure 2: Weight-for-age z-score distribution 
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